Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on December 18, 2007, regarding events occurring on December 12, 2007. The filing addresses significant changes in executive leadership and compensatory arrangements for named executive officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The financial data presented is limited to executive compensation adjustments.
| Executive Officer | Title | 2007 Base Salary | 2008 Base Salary | Option Award (Shares) |
|---|---|---|---|---|
| John M. Maraganore, Ph.D. | Chief Executive Officer | $415,000 | $525,000 | 150,600 |
| Barry E. Greene | President and Chief Operating Officer | $300,000 | $350,000 | 80,000 |
| Patricia L. Allen | Vice President of Finance and Treasurer | $210,746 | $227,830 | 32,625 |
Option Details: The exercise price for all options is $31.39 per share. Vesting begins at 25% on the first anniversary of the grant date, followed by 6.25% every three months thereafter until the fourth anniversary.
Material Changes
- Leadership Transition: Barry E. Greene was appointed President and Chief Operating Officer. John M. Maraganore, Ph.D., stepped down as President but continues as Chief Executive Officer.
- Compensation Increases: Base salaries for all named executive officers were increased effective January 1, 2008.
- Equity Grants: New stock options were awarded to the named executive officers under the 2004 Stock Incentive Plan and the Executive Stock Option Bonus Plan for 2007.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of risks and contingencies. It is strictly a disclosure of corporate governance and compensation actions.
Investor Verification Checklist
- Verify the impact of the leadership transition on the company's strategic direction.
- Confirm the total dilution impact of the 263,225 new stock options granted.
- Review the vesting schedule to understand future compensation obligations.
- Check the stock price performance relative to the $31.39 exercise price.